428 related articles for article (PubMed ID: 30232509)
41. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
42. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.
Düngen HD; Tscholl V; Obradovic D; Radenovic S; Matic D; Musial Bright L; Tahirovic E; Marx A; Inkrot S; Hashemi D; Veskovic J; Apostolovic S; von Haehling S; Doehner W; Cvetinovic N; Lainscak M; Pieske B; Edelmann F; Trippel T; Loncar G
ESC Heart Fail; 2018 Apr; 5(2):288-296. PubMed ID: 29476612
[TBL] [Abstract][Full Text] [Related]
43. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
44. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study.
Charitakis E; Walfridsson H; Alehagen U
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393
[TBL] [Abstract][Full Text] [Related]
45. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
Suzuki S; Sugiyama S
Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
[TBL] [Abstract][Full Text] [Related]
46. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
Pervez MO; Winther JA; Brynildsen J; Strand H; Christensen G; Høiseth AD; Myhre PL; Røysland R; Lyngbakken MN; Omland T; Røsjø H
Biomarkers; 2018 Nov; 23(7):654-663. PubMed ID: 29733687
[TBL] [Abstract][Full Text] [Related]
47. Mid-regional pro-adrenomedullin: an indicator of the failing Fontan circuit in patients with univentricular hearts?
Kaiser R; Abdul-Khaliq H; Wilkens H; Herrmann E; Raedle-Hurst TM
Eur J Heart Fail; 2014 Oct; 16(10):1082-8. PubMed ID: 25201135
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department.
Bahrmann P; Christ M; Hofner B; Bahrmann A; Achenbach S; Sieber CC; Bertsch T
Eur Heart J Acute Cardiovasc Care; 2016 Dec; 5(8):568-578. PubMed ID: 26483565
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
50. Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender : Results from the PROBE-HF study.
Ballo P; Betti I; Barchielli A; Balzi D; Castelli G; De Luca L; Gheorghiade M; Zuppiroli A
Clin Res Cardiol; 2016 May; 105(5):421-31. PubMed ID: 26547915
[TBL] [Abstract][Full Text] [Related]
51. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
Palladini G; Barassi A; Perlini S; Milani P; Foli A; Russo P; Albertini R; Obici L; Lavatelli F; Sarais G; Casarini S; Moratti R; Melzi d'Eril GV; Merlini G
Amyloid; 2011 Dec; 18(4):216-21. PubMed ID: 22070520
[TBL] [Abstract][Full Text] [Related]
52. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
Ahluwalia N; Blacher J; Szabo de Edelenyi F; Faure P; Julia C; Hercberg S; Galan P
Atherosclerosis; 2013 Jun; 228(2):478-84. PubMed ID: 23582589
[TBL] [Abstract][Full Text] [Related]
55. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
57. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF.
O'Brien RJ; Squire IB; Demme B; Davies JE; Ng LL
Eur J Heart Fail; 2003 Aug; 5(4):499-506. PubMed ID: 12921811
[TBL] [Abstract][Full Text] [Related]
58. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
van Diepen S; Newby LK; Lopes RD; Stebbins A; Hasselblad V; James S; Roe MT; Ezekowitz JA; Moliterno DJ; Neumann FJ; Reist C; Mahaffey KW; Hochman JS; Hamm CW; Armstrong PW; Granger CB; Theroux P;
Int J Cardiol; 2013 Oct; 168(3):2127-33. PubMed ID: 23394896
[TBL] [Abstract][Full Text] [Related]
59. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
[TBL] [Abstract][Full Text] [Related]
60. Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.
Yao Y; Feng L; Sun Y; Wang S; Sun J; Hu B
BMC Cardiovasc Disord; 2021 May; 21(1):264. PubMed ID: 34049488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
